The National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) awarded Duke University a $241,500 Project Grant under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847) to study the regulation of metabolic diseases by the human commensal bacterium Clostridium immunis. The overarching goal is to determine the mechanism by which an exopolysaccharide (EPS) secreted by C. immunis decreases visceral adiposity, a key risk factor for type 2 diabetes and...
The National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) awarded a $1,561,974 Project Grant under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847) to Syntis Bio Inc. in Dorchester, MA. The goal of this Fast-Track SBIR project is to develop an oral pill that blocks nutrient absorption in the duodenum, mimicking the effects of gastric bypass surgery for obesity treatment. Syntis Bio will optimize their Gastrointestinal Synthetic...
The U.S. National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) awarded a $222,500 Project Grant under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847) to the Beckman Research Institute of the City of Hope. The grant supports research to understand how conjugated bile acids regulate metabolism after bariatric surgery, with the goal of developing safer and more affordable treatments for obesity and fatty liver disease. Key activities include...
The National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) awarded Biotherapeutics, Inc. a $359,625 Project Grant under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847). The grant supports the development of next-generation, once-daily oral therapeutic candidates for the treatment of pre-diabetes and type 2 diabetes. Key research objectives include evaluating the therapeutic efficacy of the lead drug candidate on lipid metabolism, insulin...
This federal Project Grant award from the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847), is supporting the development of novel therapeutics for obesity and type 2 diabetes. The $1,021,719 grant, awarded to Emmyon, Inc., will fund preclinical studies to advance the development of a proprietary small molecule compound (EMMY1-25) that promotes weight loss without muscle loss and...
The National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) awarded a $1,600,000 Project Grant under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847) to the Icahn School of Medicine at Mount Sinai. The project, titled "Decoding Endocrine and Paracrine Communication Through Mammokines," aims to discover new signaling molecules from the mammary gland that influence metabolic function and the progression of obesity and type 2...
The National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) awarded a $136,449 project grant under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847) to The Regents of the University of California, Berkeley. The award, which runs from December 1, 2024 to November 30, 2026, will fund research to optimize the use of CRISPR-mediated gene downregulation to rapidly test whether genes linked to human obesity are required for the function of...
This Project Grant award of $168,900 from the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847) supports research to determine how the commensal bacterium Blautia activates signaling in gut epithelial cells to benefit host metabolism and mucosal health. The research aims to identify the synthetic processes and microbial products of Blautia that augment activation of enteroendocrine...
The National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) awarded a $1,712,226 Project Grant under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847) to Orphagen Pharmaceuticals, Inc. The grant supports the development of a novel, first-in-class class of small molecule antagonists that inhibit the gut migration of activated T cells, which is a promising therapeutic approach for treating inflammatory bowel disease (IBD). Preliminary data...
The National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847), awarded a $663,097 Project Grant to Merrimack College to evaluate the impact of the updated federal nutrition standards for school meals in the United States. The study aims to examine compliance with the new standards, potential product reformulation, changes in school meal participation rates, students' dietary intakes,...
The National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) awarded a $582,825 Project Grant under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847) to Epic Nutrition For Y LLC in Troy, Michigan. The grant supports research to develop a novel probiotic, Clostridium cochlearium 2316 (CC), as a safe, low-cost, and long-term dietary supplement/medical food for managing obesity and insulin resistance. The 2-year project aims to assess the pharmacokinetics, long-term efficacy, and safety of CC supplementation in diet-induced obese mice, laying the groundwork for future clinical trials. Successful outcomes could have a significant public health impact by providing a new preventive and complementary nutritional intervention for the obesity epidemic in the United States.